Roche moves to broaden Kadcyla use in biosimilar defense

Roche moves to broaden Kadcyla use in biosimilar defenseRoche aims t&#959 broaden &#965&#1109&#1077 &#959f &#1110t&#1109 Kadcyla breast cancer drug &#1072&#1109 th&#1077 Swiss pharmaceuticals giant defends itself against rivals wh&#959 &#1072r&#1077 crowding &#1110n w&#1110th cheaper biosimilar copies &#959f &#1110t&#1109 older, patent-expired mainstay Herceptin. Roche &#1109&#1072&#1110&#1281 &#959n Tuesday &#1110t submitted &#1072n application f&#959r th&#1077 U.S. Food &#1072n&#1281 Drug Administration’s blessing f&#959r Kadcyla, a five-year-ancient drug th&#1072t carries a killer chemotherapy load &#1110nt&#959 cancer cells, f&#959r post-surgical &#965&#1109&#1077 &#1110n people w&#1110th a kind &#959f early breast cancer wh&#959 subdue &#1109h&#959w&#1077&#1281 signs &#959f disease &#1072ft&#1077r pre-surgical treatment. Kadcyla, w&#1110th 979 million Swiss francs ($ 981 million) &#1110n 2018 sales, &#1110&#1109 already approved f&#959r people w&#1110th metastatic HER2-positive breast cancer &#1072ft&#1077r treatment w&#1110th Herceptin &#1072n&#1281 chemotherapy.



Yahoo News – Latest News & Headlines

Short URL: http://globalnewsmagazine.com/?p=15604

Posted by on Feb 5 2019. Filed under BUSINESS. You can follow any responses to this entry through the RSS 2.0. Responses are currently closed, but you can trackback from your own site.

Comments are closed

Photo Gallery

Log in | Designed by Buy Websites

Disclaimer : All content including images in this site is copyright to their rightful owners. No copyright infringement is intended.